Ben Comer

Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation.

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.

Early efforts in the pharma space to harness the engagement factor in game technology focused on delivering a fun experience, with a tackedon educational component. Today's games bring behavior change to the forefront, incorporating social dynamics, mobility, and increasingly sophisticated mechanics.

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations.

Social networks existed long before Mark Zuckerberg came along. What hasn’t existed until recently are the tools, metrics and case studies necessary to understand how physicians influence each other within professional networks, and how these relationships can be used to change prescribing behavior.

If you really want to know what’s on a patient’s mind, it’s best to skip the small talk and go straight to the brain waves, as demonstrated by Neuro Insight CEO Pranav Yadav in the lead-off presentation yesterday at Chandler Chicco’s Pioneers in Digital Health conference.

Worried they might get taken for a ride, university tech transfer offices are beginning to hire ex-pharma and biotech personnel to help negotiate deals with industry.

Provisions in the Affordable Care Act (ACA) drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011, according to research published on Wednesday.

What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK?

This June, Californians will be asked whether cigarette smokers should subsidize research to treat diseases related to smoking cigarettes.

In judging the Prometheus patents invalid, the Supreme Court may have shown its hand on the upcoming Myriad Genetics case.

Over a hundred public companies, dozens of clinicians, and several regulators participated in investment firm Leerink Swann’s 2012 Healthcare Conference in mid-February.

Jim Currie and Baber Ghauri talk to Pharm Exec about making connections that resonate with audiences in a digital world.

SAS’s Brad Sitler talks about the importance of incremental sales, customer proximity, and anticipating a compensation model based on health outcomes

With an all-important FDA decision on carfilzomib scheduled for July 27, Onyx hopes to graduate to the next stage of commercial success. For a feature-length profile of Onyx and CEO Tony Coles

A new collaboration will move FDA closer to predicting adverse events – before they happen – as part of the regulatory process

At the digital marketing-focused ePharma Summit in New York this week, many of the problems and frustrations related to the “big three” – Facebook, Twitter and YouTube – were hashed out for umpteenth time.

Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.

Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".

Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.

Forget illegal immigrants, it is machines that are stealing American jobs. For some medical practice areas, however, digital details haven’t sufficiently stepped in where their human sales rep predecessors have stepped (or have been pushed) out, according to a survey of U.S. physicians.

Outgoing CEO Michael McCallister said one of Humana’s primary strategies going forward is to keep patients out of hospitals and other healthcare institutions, when possible.

Those in favor of a less is more approach to FDA social media guidelines got what they wanted for the holidays: a trim, 15-page document on how to respond to unsolicited off-label comments

A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit.

Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year?

Josef von Rickenbach, President & CEO, Parexel

Three Decades of Politics and Pop Culture ... on Drugs

'Like' and 'Dislike' practices in the virtual Facebook pharmaceutical world.

Taking Onyx Pharmaceuticals to new heights – CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood.

What do our genetics tell us about our predisposition to certain diseases?